Last update 29 Sep 2025

Daraxonrasib

Overview

Basic Info

Drug Type
Non-degrading molecular glue
Synonyms
A122, RMC 6236, RMC-6236
+ [1]
Action
inhibitors
Mechanism
KRAS inhibitors(GTPase KRas inhibitors), RAS inhibitors(RAS type GTPase family inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationBreakthrough Therapy (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC44H58N8O5S
InChIKeyFVICRBSEYSHKFY-UHFFFAOYSA-N
CAS Registry2765081-21-6

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-Small Cell Lung CancerPhase 3
United States
06 May 2025
Non-Small Cell Lung CancerPhase 3
Japan
06 May 2025
Non-Small Cell Lung CancerPhase 3
Belgium
06 May 2025
Metastatic Pancreatic Ductal AdenocarcinomaPhase 3
United States
16 Oct 2024
Metastatic Pancreatic Ductal AdenocarcinomaPhase 3
Japan
16 Oct 2024
Metastatic Pancreatic Ductal AdenocarcinomaPhase 3
France
16 Oct 2024
Metastatic Pancreatic Ductal AdenocarcinomaPhase 3
Germany
16 Oct 2024
Metastatic Pancreatic Ductal AdenocarcinomaPhase 3
Italy
16 Oct 2024
Metastatic Pancreatic Ductal AdenocarcinomaPhase 3
Spain
16 Oct 2024
Adenocarcinoma of large intestinePhase 2
United States
24 May 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
Pancreatic Ductal Adenocarcinoma
Second line
RAS G12X mutation | RAS mutation
83
fyvlivcygr(acdzpsskzu) = ycjmbavqfn bqximnjcmp (llwbetxjtu )
Positive
10 Sep 2025
(RAS G12X mutation)
fyvlivcygr(acdzpsskzu) = tjegekkfyh bqximnjcmp (llwbetxjtu )
Phase 1
Pancreatic Ductal Adenocarcinoma
First line
RAS mutations
40
thzkjgdmys(ljplwimvzx) = zgllxanpoc skkmtzxtfl (oriiyzcegb )
Positive
10 Sep 2025
Phase 1
40
fqpzrbdejz(sfckzlxuzm) = lmeibgueur jixghbtjbt (piusuubhty )
Positive
10 Sep 2025
NEWS
ManualManual
Not Applicable
-
nmzkuioyxy(maozdvknfo) = zvkqqszkde rejvvmccgm (rsisgasprp )
Positive
10 Jul 2025
(TPS<50%)
nmzkuioyxy(maozdvknfo) = peglfrbykb rejvvmccgm (rsisgasprp )
Not Applicable
33
lbnzehdvry(uwhklztuyi) = rxadbxurtc lgaxhpynil (npprfawyxr )
Positive
10 May 2025
Phase 1/2
17
(PD-L1 TPS ≥ 50%)
ysexapouzi(ohsgkogcli) = wkxtuimyua mvkzlgunok (ivmnxkwtwj )
Positive
07 May 2025
Daraxonrasib + Pembrolizumab + Chemotherapy
(PD-L1 TPS < 50%)
ysexapouzi(ohsgkogcli) = vjeutchheh mvkzlgunok (ivmnxkwtwj )
Phase 1
26
nlywpdwjpa(uocpdllgxi) = axvgsubppd wgaxsfgxtf (hdevpveroe )
Positive
07 May 2025
Phase 1
RAS Mutation Non-Small Cell Lung Cancer
Second line | First line
RAS Mutation (Activating)
73
Daraxonrasib 120-220 mg
pjgejfesof(ycyhyxxhoc) = npcayuzeqq wnjqsbsgwa (smxkfendig )
Positive
27 Mar 2025
Phase 1
436
(KRAS G12X + PDAC)
sqobddrbcu(lkpdsfeiji) = dsxblhtsyo lchhivicab (mjinlqtzrv, 8.5 - NE)
Positive
02 Dec 2024
RMC-6236 monotherapy
(RAS mutation + PDAC)
sqobddrbcu(lkpdsfeiji) = jzivsauuyz lchhivicab (mjinlqtzrv, 5.9 - NE)
Phase 1
74
wirgspxnqu(xmdiwhbeaq) = wqhgxxlqoc huagkotedu (iwhwhqjysc )
Positive
02 Dec 2024
wirgspxnqu(xmdiwhbeaq) = cinwuexclh huagkotedu (iwhwhqjysc )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free